IPSEN (IPN.PA)
Develops cancer drugs and specialty medicines for rare diseases and neurological disorders
160.40+0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+55.4%
The outlook
Ipsen (IPN.PA) is trading at 160.4, positioned well above its 50- and 200-day moving averages and near the upper end of its 52-week range. Analyst consensus leans toward Buy, though the average price target sits roughly 1% above the current level. The stock carries a trailing P/E of 30.2 and shows a leaning-bullish technical posture overall.
What’s behind the score
Analyst consensusBuy — 2.4 avg of 15 analysts
Price trendAbove its 50- & 200-day averages
52-week range82% of the way from its 52-week low to high
Price targetAvg target +1% vs current price
Analyst price target
~12-month · 15 analysts161.67average target+0.8% vs now
Now 160.40
Low 117.00High 235.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$13.26B
52-wk high
173.50
52-wk low
101.90
50-day avg
160.36
200-day avg
146.29
Trailing P/E
30.2